Aims and Scope of Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058. Less
Key Metrics
CiteScore 

5.6
Eigenfactor 

0.001 - 0.005
H-Index 

52
Impact Factor 

< 5
SJR 

Q1Pharmacology

SNIP 

0.8
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Opinion on Emerging Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Opinion on Emerging Drugs
Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs
- 27 Jul 2026
- Expert Opinion on Emerging Drugs
Drug discovery progress in targeting the renin–angiotensin–aldosterone system for heart failure
- 23 Jul 2026
- Expert Opinion on Emerging Drugs
Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas
- 22 Jul 2026
- Expert Opinion on Emerging Drugs
σ1 receptor agonists: the new trend or an emerging therapeutic option?
- 2 Jul 2026
- Expert opinion on emerging drugs
Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond
- 24 Jun 2026
- Expert Opinion on Emerging Drugs
Obefazimod (ABX464) for Moderate-to-Severe Crohn’s disease: clinical development of a novel oral therapeutic approach
- 22 Jun 2026
- Expert Opinion on Emerging Drugs
Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs
- 27 Jul 2026
- Expert Opinion on Emerging Drugs
Drug discovery progress in targeting the renin–angiotensin–aldosterone system for heart failure
- 23 Jul 2026
- Expert Opinion on Emerging Drugs
Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas
- 22 Jul 2026
- Expert Opinion on Emerging Drugs
σ1 receptor agonists: the new trend or an emerging therapeutic option?
- 2 Jul 2026
- Expert opinion on emerging drugs
Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond
- 24 Jun 2026
- Expert Opinion on Emerging Drugs
Obefazimod (ABX464) for Moderate-to-Severe Crohn’s disease: clinical development of a novel oral therapeutic approach
- 22 Jun 2026
- Expert Opinion on Emerging Drugs